India’s pharma sector is staring at a significant tailwind that comes in the form of GLP-1 opportunity. Brokerage Elara Capital in a note said that GLP-1 could become first line therapy in diabetes and obesity and could replace other drug classes in …
Diabetes wave to fuel Indian pharma rally in 2026. Elara Capital picks 9 stocks for up to 43% gains
